|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.
|
31558693 |
2019 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C.
|
31831303 |
2019 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was to determine the changes of liver stiffness (LS), controlled attenuation parameter (CAP) value and FIB-4 and their associated factors for chronic hepatitis C (CHC) patients who underwent direct-acting antivirals (DAAs).
|
30939158 |
2019 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
|
30151861 |
2019 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
|
30403744 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare on-treatment and off-treatment parameters acquired using acoustic radiation force impulse elastography, the Fibrosis-4 (FIB-4) index, and aspartate aminotransferase-to-platelet ratio index (APRI) in patients with chronic hepatitis C (CHC).
|
29293628 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) are commonly used compound surrogates for advanced fibrosis in chronic hepatitis C (CHC) patients.
|
29953518 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Does Incorporating Change in APRI or FIB-4 Indices Over Time Improve the Accuracy of a Single Index for Identifying Liver Fibrosis in Persons With Chronic Hepatitis C Virus Infection?
|
27875352 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, MLP is better than APRI, FIB-4, and REPTree for predicting advanced fibrosis for patients with chronic hepatitis C.
|
29279441 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in DAA era.
|
31829993 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.
|
29069254 |
2017 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.
|
28425016 |
2017 |